Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | BTK | Q06187 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23389123 | 0.90 | EPHX2 (0.46) | EPHX2ALDH1A1KDM4E | |
| SCHEMBL23389124 | 0.90 | EPHX2 (0.46) | EPHX2ALDH1A1KDM4E | |
| SCHEMBL23419215 | 0.77 | EPHX2 (0.63) | EPHX2 | |
| SCHEMBL23418851 | 0.77 | EPHX2 (0.63) | EPHX2 | |
| SCHEMBL25993140 | 0.76 | EPHX2 (0.41) | GFEREPHX2RAB9AMAPTBTK | |
| SCHEMBL23389214 | 0.73 | EPHX2 (0.42) | EPHX2MAPT | |
| SCHEMBL23389211 | 0.73 | EPHX2 (0.42) | EPHX2MAPT | |
| SCHEMBL25992522 | 0.72 | BTK (0.38) | EPHX2GAABTK | |
| SCHEMBL23389085 | 0.71 | CA1 (0.49) | EPHX2RAB9AALDH1A1 | |
| SCHEMBL23389086 | 0.71 | CA1 (0.49) | EPHX2RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | CASP6, CASP1, CASP10 | GFER 3736/4885EPHX2 3551/4885RAB9A 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.